• Mass General Brigham, a global leader in cardiovascular care, to participate in SAPPHIRE Study
• Dr. Ron Blankstein named as Principal Investigator of the study
• SAPPHIRE Study expected to launch in early 2026 with 6-8 high-quality U.S. centers

Artrya Limited (ASX: AYA), a medical technology company commercializing its Salix® AI-powered cloud platform for the assessment and management of coronary artery disease, has announced that Mass General Brigham, a global leader in cardiovascular care and medical research, has agreed to be a participant in the upcoming SAPPHIRE Study. Mass General Brigham is recognized globally for its outstanding research capabilities, extensive clinical trial experience, and renowned Cardiovascular Research Center. With more than 250,000 cardiology outpatient visits annually, the organization's strong presence across New England and the Northeast will be invaluable to Artrya throughout the study and as the company expands its commercial footprint in the United States. Dr. Ron Blankstein, Director of Cardiac Computed Tomography & Preventive Cardiologist at Brigham and Women's Hospital, has been named as the Principal Investigator of the SAPPHIRE Study. Dr. Blankstein is a highly accomplished cardiologist, past president of the Society of Cardiovascular Computed Tomography, and has served on the Board of Directors of the American Society of Preventive Cardiology. The SAPPHIRE Study is expected to launch in early 2026 and will assess how Salix can detect coronary artery disease earlier and more effectively. Mass General Brigham joins Piedmont Healthcare and the Huntsville Hospital Heart Center as confirmed participants in the study, which will be a retrospective, multi-center, real-world evaluation of the clinical and prognostic value of Artrya's Salix® Plaque Analysis and its proprietary Plaque Dispersion Score (PDS).

Artrya is excited to have Mass General Brigham, a global leader in cardiovascular care and research, participate in the SAPPHIRE Study. The inclusion of this prestigious, high-volume U.S. cardiology site will be invaluable as the company works to advance the prevention and treatment of early-stage coronary heart disease through its innovative Salix® platform.